NCT04142437: Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

NCT04142437
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment with larotrectinib or other kinase inhibitor with TRK inhibition; Patients with NTRK gene amplification or NTRK point mutation
https://ClinicalTrials.gov/show/NCT04142437

Comments are closed.

Up ↑